Objective: To investigate the changes of serum vascular endothelial growth factor (VEGF), solubleinterleukin-2 receptor (SIL-2R) and hepatocyte growth factor (HGF) contents in patients with primaryhepatocellular carcinoma (HCC) before and after percutaneous microwave coagulation therapy (PMCT) anddetermine their clinical significance. Materials and
Methods: Fasting venous blood (3 mL) from 81 patientswith primary HCC diagnosed by pathology was collected in the mornings 1 day before PMCT, and 1 day, 7days and 1 month after PMCT, and then the serum was separated and stored in -70℃. The contents of VEGF,SIL-2R and HGF were detected by enzyme linked immunosorbent assay (ELISA).
Results: The serum VEGF,SIL–2R and HGF contents in 81 patients with primary HCC had obviously dynamic changes before and afterPMCT. By comparison to 1 day after PMCT with pre-operation, there was no statistical significance regardingVEGF and SIL–2R contents (P>0.05), but HGF content showed significant difference (P<0.01). Compared withpre-operation, VEGF, SIL-2R and HGF contents 7 days and 1 month after PMCT all manifested significantdifferences (P<0.01). By comparison to 7 days with 1 month after PMCT, there was no statistical significanceregarding the VEGF content (P>0.05), whereas SIL-2R and HGF contents showed significant change (P<0.01).
Conclusions: The contents of serum VEGF, SIL-2R and HGF have obviously dynamic changes in primary HCCbefore and after PMCT, and their joint detection is expected to be an effective hematologic evaluation index ofPMCT for primary HCC.